Glioblastoma Study Links Oligodendrocytes to Tumor Growth

Study Combining Spatial Transcriptomics and Computational Analyses Identifies a Role for Oligodendrocytes in Glioblastoma Progression

Full Article

by Christos Evangelou, MSc, PhD – Medical Writer and Editor

Researchers at The Hospital for Sick Children, McMaster University, and the University of Toronto in Canada found that glioblastoma cells recruit oligodendrocytes and turn them into tumor-promoting cells that promote tumor growth and recurrence. They also identified molecular pathways that regulate the interaction between glioblastoma cells and oligodendrocytes, and showed that blocking one of these pathways with an FDA-approved drug extends survival in preclinical models.

“Hopefully, our study helps readers see that glioblastoma isn’t just an isolated tumor, but it behaves like a complex ecosystem, with diverse cell types communicating extensively,” said Kui Zhai, PhD, research associate at McMaster University and the co-first author of the study. “Interestingly, oligodendrocytes, which are known to play a protective role in the brain, actually promote tumor growth. This finding highlights how the tumor microenvironment can be hijacked by cancer.”

The study was published in Neuron.

Study Rationale

Despite standard treatment with surgical resection, radiotherapy, and temozolomide chemotherapy, median survival in patients with glioblastoma is around 15 months, and the rate of recurrence is high. This dismal prognosis reflects both the tumor’s intrinsic aggressiveness and […]

Continue reading this article

This exclusive, subscriber only, article is for those who share a passion for pathology.
Join our forever free community to continue reading.

Summary

A recent study by researchers from The Hospital for Sick Children, McMaster University, and the University of Toronto has uncovered a novel mechanism by which glioblastoma cells exploit oligodendrocytes to promote tumor growth and recurrence. The study demonstrates that glioblastoma cells actively recruit oligodendrocytes via the CX3CL1/CX3CR1 signaling axis, transforming them into reactive cells that secrete pro-tumorigenic factors, particularly CCL5 (RANTES). This cytokine engages CCR5 on glioma stem cells, enhancing their proliferation and self-renewal. Using single-cell RNA sequencing, spatial transcriptomics, and functional assays, the researchers identified oligodendrocyte-lineage cells as consistently enriched in recurrent glioblastoma, with reactive states resembling those seen in neuroinflammatory conditions. Key findings include the discovery that blocking CCR5—either genetically or with the FDA-approved HIV drug maraviroc—reduced tumor growth and prolonged survival in preclinical models. High CCR5 expression correlated with worse clinical outcomes in glioblastoma patients, suggesting its potential as a therapeutic target. Additionally, the study highlights the broader concept of glioblastoma as a complex ecosystem where non-tumor cells are co-opted to support malignancy. The clinical significance lies in the identification of two actionable targets: CX3CR1 to prevent oligodendrocyte recruitment and CCR5 to disrupt tumor-promoting signaling. While the study was conducted in immunodeficient models, the findings open avenues for repurposing maraviroc or similar CCR5 antagonists in glioblastoma therapy. Future research will explore the role of oligodendrocyte progenitor cells and the molecular mechanisms underlying CCR5-driven tumor progression. This work underscores the importance of targeting the tumor microenvironment and offers a promising translational strategy to improve outcomes in this aggressive malignancy.